Parents' views on the acceptability of a COVID-19 vaccine for their children: A cross-sectional study in Abu Dhabi-United Arab Emirates.

BACKGROUND: The United Arab Emirates had approved the COVID-19 vaccine for children. Assessing parents' acceptance of the vaccine for their children will influence decision-making in the COVID-19 vaccine roll-out. METHOD: Parents registered inthe AbuDhabiDepartmentofEducation (12,000 families) were invitedtocompleteanonlinequestionnaire from 8th September 2021 to 17th October 2021. Out of the 12,000 families, 2510 (21%) participants answered the survey. The questionnaire investigated the parents' attitudes and beliefs regarding the COVID-19 vaccine. RESULTS: The vaccination rate among this group of respondents was high, with 2255 (89.9%) having received two doses and 1002 (45.5%) having already received a booster dose. Acceptance of the respondents to vaccinate their children was high, (75.1%) said they would vaccinate their children, with 64.4% reporting that they would immediately vaccinate their children if the vaccine were made available. Determinants of COVID-19 child vaccination acceptance included the respondent's vaccination status-i.e., if the respondent is already vaccinated (OR 4.96 [2.89-8.53]) or has taken the third dose (OR 2.37 [1.4-4.01])-their children's age (OR 1.11 [1.30-1.18] for older children), and their trust in the following information sources: the government (OR 2.53 [1.61-3.98]), health care providers (OR 1.98 [1.2-3.24]), or social media (OR 2.17 [1.22-3.88]). Increased level of education had a negative impact on the acceptance of giving the vaccine to children (OR 0.63 [0.52-0.77]); fear of side effects OR 0.000164 (0.000039-0.001) was another determinant. The main factor that encouraged parents to give their children the vaccine was to protect their child's health as reported by 1537 (55.5%) participants. CONCLUSION: The Abu Dhabi community is highly accepting of the vaccine for their children. Future studies of how this vaccine acceptance can influence the pandemic are needed.

Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates.

The effectiveness of the inactivated BBIBP-CorV vaccine against severe COVID-19 outcomes (hospitalization, critical care admission and death due to COVID-19) and its long-term effectiveness have not been well characterized among the general population. We conducted a retrospective cohort study using electronic health records of 3,147,869 adults, of which 1,099,886 vaccinated individuals were matched, in a 1:1 ratio to 1,099,886 unvaccinated persons. A Cox-proportional hazard model with time varying coefficients was used to assess the vaccine effectiveness adjusting for age, sex, comorbidity, ethnicity, and the calendar month of entry into the study. Our analysis showed that the effectiveness was 79.6% (95% CI, 77.7 to 81.3) against hospitalization, 86% (95% CI, 82.2 to 89.0) against critical care admission, and 84.1% (95% CI, 70.8 to 91.3) against death due to COVID-19. The effectiveness against these severe outcomes declined over time indicating the need for booster doses to increase protection against severe COVID-19 outcomes.